PMID- 28711969
OWN - NLM
STAT- MEDLINE
DCOM- 20180814
LR  - 20220318
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 41
IP  - 2
DP  - 2018 Feb
TI  - Hyperuricemia is associated with an increased prevalence of paroxysmal atrial 
      fibrillation in patients with type 2 diabetes referred for clinically indicated 
      24-h Holter monitoring.
PG  - 223-231
LID - 10.1007/s40618-017-0729-4 [doi]
AB  - PURPOSE: Several studies have reported an association between hyperuricemia and 
      increased risk of permanent atrial fibrillation (AF) in patients with and without 
      type 2 diabetes mellitus (T2DM). Currently, no published data are available on 
      the relationship between hyperuricemia and risk of paroxysmal AF. METHODS: We 
      retrospectively evaluated 245 T2DM outpatients without pre-existing AF, cancer, 
      cirrhosis and end-stage renal disease, who underwent a 24-h ECG-Holter monitoring 
      for various clinical indications. Hyperuricemia was defined as a serum uric acid 
      level >7 mg/dl for men and >6 mg/dl for women or allopurinol use. The diagnosis 
      of paroxysmal AF was confirmed in affected individuals on the basis of 24-h 
      ECG-Holter monitoring by experienced cardiologists. RESULTS: Hyperuricemia was 
      observed in 59 (24.1%) patients, whereas paroxysmal AF was found in 11 (4.5%) 
      patients. The prevalence of paroxysmal AF was higher in patients with 
      hyperuricemia than in those without hyperuricemia (10.2 vs. 2.7%, p = 0.026). 
      Logistic regression analysis showed that hyperuricemia was associated with an 
      increased risk of prevalent paroxysmal AF. This association remained significant 
      even after adjustment for age, metabolic syndrome and chronic kidney disease 
      (adjusted-odds ratio 4.01, 95% CI 1.08-14.9; p = 0.039). Similar results were 
      found when we used serum uric acid levels as a continuous measure. CONCLUSIONS: 
      This study shows for the first time that hyperuricemia is independently 
      associated with an approximately fourfold increased risk of prevalent paroxysmal 
      AF in patients with T2DM. These findings may partly explain the increased risk of 
      permanent atrial fibrillation and cardiovascular death observed among patients 
      with hyperuricemia.
FAU - Mantovani, A
AU  - Mantovani A
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy. alessandro.mantovani24@gmail.com.
FAU - Rigolon, R
AU  - Rigolon R
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy.
FAU - Civettini, A
AU  - Civettini A
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy.
FAU - Bolzan, B
AU  - Bolzan B
AD  - Section of Cardiology, Department of Medicine, University and Azienda Ospedaliera 
      Universitaria Integrata of Verona, Verona, Italy.
FAU - Morani, G
AU  - Morani G
AD  - Section of Cardiology, Department of Medicine, University and Azienda Ospedaliera 
      Universitaria Integrata of Verona, Verona, Italy.
FAU - Bonapace, S
AU  - Bonapace S
AD  - Division of Cardiology, "Sacro Cuore" Hospital, Negrar, VR, Italy.
FAU - Dugo, C
AU  - Dugo C
AD  - Division of Cardiology, "Sacro Cuore" Hospital, Negrar, VR, Italy.
FAU - Zoppini, G
AU  - Zoppini G
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy.
FAU - Bonora, E
AU  - Bonora E
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy.
FAU - Targher, G
AU  - Targher G
AD  - Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, 
      University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale A. 
      Stefani, 1, 37126, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170715
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - Aged
MH  - Atrial Fibrillation/blood/*epidemiology
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/blood/*physiopathology
MH  - Female
MH  - Humans
MH  - Hyperuricemia/blood/*complications/pathology
MH  - Italy/epidemiology
MH  - Male
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Uric Acid/*blood
OTO - NOTNLM
OT  - Atrial fibrillation
OT  - Hyperuricemia
OT  - Paroxysmal atrial fibrillation
OT  - Type 2 diabetes
EDAT- 2017/07/18 06:00
MHDA- 2018/08/15 06:00
CRDT- 2017/07/17 06:00
PHST- 2017/05/23 00:00 [received]
PHST- 2017/07/09 00:00 [accepted]
PHST- 2017/07/18 06:00 [pubmed]
PHST- 2018/08/15 06:00 [medline]
PHST- 2017/07/17 06:00 [entrez]
AID - 10.1007/s40618-017-0729-4 [pii]
AID - 10.1007/s40618-017-0729-4 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2018 Feb;41(2):223-231. doi: 10.1007/s40618-017-0729-4. Epub 
      2017 Jul 15.